Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the selection, cultivation, processing, and sale of medicinal materials in China. It offers Ganoderma lucidum spore powder and brand broken cell wall powder, as well as broken wall Ganoderma lucidum spore powder granules and powder tablets; Tiepi Fengdou granules; and Tiepi Fengdou Ganoderma lucidum extracts. The company offers its products … Read more
Zhejiang Shouxiangu Pharm Co (603896) - Total Liabilities
Latest total liabilities as of September 2025: CN¥841.89 Million CNY
Based on the latest financial reports, Zhejiang Shouxiangu Pharm Co (603896) has total liabilities worth CN¥841.89 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Shouxiangu Pharm Co - Total Liabilities Trend (2012–2024)
This chart illustrates how Zhejiang Shouxiangu Pharm Co's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Shouxiangu Pharm Co Competitors by Total Liabilities
The table below lists competitors of Zhejiang Shouxiangu Pharm Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thai Vegetable Oil Public Company Limited
BK:TVO
|
Thailand | ฿3.48 Billion |
|
Hanza AB
ST:HANZA
|
Sweden | Skr3.08 Billion |
|
Jiangsu Tongli Risheng Machinery Co. Ltd.
SHG:605286
|
China | CN¥2.72 Billion |
|
Lindex Group
HE:LINDEX
|
Finland | €872.50 Million |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥1.01 Billion |
|
Facc AG
VI:FACC
|
Austria | €440.00 Million |
|
Alpargatas S.A
SA:ALPA3
|
Brazil | R$2.77 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Zhejiang Shouxiangu Pharm Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Shouxiangu Pharm Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Shouxiangu Pharm Co (2012–2024)
The table below shows the annual total liabilities of Zhejiang Shouxiangu Pharm Co from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥837.17 Million | -16.54% |
| 2023-12-31 | CN¥1.00 Billion | +5.51% |
| 2022-12-31 | CN¥950.67 Million | +177.64% |
| 2021-12-31 | CN¥342.41 Million | -8.27% |
| 2020-12-31 | CN¥373.28 Million | +121.77% |
| 2019-12-31 | CN¥168.31 Million | -18.61% |
| 2018-12-31 | CN¥206.79 Million | +265.38% |
| 2017-12-31 | CN¥56.60 Million | -67.69% |
| 2016-12-31 | CN¥175.17 Million | -26.21% |
| 2015-12-31 | CN¥237.38 Million | +31.56% |
| 2014-12-31 | CN¥180.43 Million | +64.24% |
| 2013-12-31 | CN¥109.85 Million | -19.01% |
| 2012-12-31 | CN¥135.64 Million | -- |